Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis

Gastroenterology

Volumn 139, Issue 1, 2010, Pages

  Czaja, Albert J ^a   Manns, Michael P ^b  

^a MAYO CLINIC   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Current and Future Therapies; Pathogenic Mechanisms; Phenotypic Diversity

Indexed keywords

ABATACEPT; ACTIN ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; BIOLOGICAL MARKER; BUDESONIDE; CALCIUM; CD3 ANTIBODY; COLECALCIFEROL; CYCLOSPORIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FORMIMINOTRANSFERASE CYCLODEAMINASE ANTIBODY; GLUCURONOSYLTRANSFERASE ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HLA DR ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE PHOSPHATASE; RECOMBINANT INTERLEUKIN 10; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR;

ADOPTIVE TRANSFER; ALOPECIA; ANEMIA; ANTIBODY PRODUCTION; AUTOIMMUNE HEPATITIS; BODY WEIGHT; BONE MARROW DEPRESSION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHILL; CHRONIC INFLAMMATION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CTLA 4 GENE; CYTOPENIA; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DNA POLYMORPHISM; DRB 1 GENE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEVER; FLU LIKE SYNDROME; GENE; GENETIC RISK; HEADACHE; HEPATITIS A; HEPATITIS B; HUMAN; HYPERGAMMAGLOBULINEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS MONONUCLEOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MENTAL INSTABILITY; MOON FACE; MYALGIA; NAUSEA; NONHUMAN; OBESITY; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; RASH; REGULATORY T LYMPHOCYTE; RELAPSE; REVIEW; RISK FACTOR; SALVAGE THERAPY; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTOPENIA; TNFA 2 GENE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TYROSINE PHOSPHATASE CD45 GENE; UNSPECIFIED SIDE EFFECT; VITAMIN D RECEPTOR GENE; VOMITING;

EID: 77953889134     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.04.053     Document Type: Review

References (150)

1. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929-938
2. Manns M.P., Czaja A.J., Gorham J.D., et al. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 51 (2010) 2193-2213
3. Czaja A.J. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 1 (2007) 113-128
4. Czaja A.J. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol 51 (2005) 313-333
5. Czaja A.J., and Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol 15 (2009) 2314-2328
6. Czaja A.J. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis 29 (2009) 315-330
7. Czaja A.J. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci (2010 Jan 27) [Epub ahead of print]
8. Kogan J., Safadi R., Ashur Y., et al. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 35 (2002) 75-81
9. Feld J.J., Dinh H., Arenovich T., et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42 (2005) 53-62
10. Porta G., Gayotto L.C., and Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Pediatr Gastroenterol Nutr 11 (1990) 138-140
11. Kessler W.R., Cummings O.W., Eckert G., et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2 (2004) 625-631
12. Maggiore G., Porta G., Bernard O., et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 116 (1990) 280-282
13. Miyake Y., Iwasaki Y., Terada R., et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 23 (2006) 1347-1353
14. Burgart L.J., Batts K.P., Ludwig J., et al. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol 19 (1995) 699-708
15. Singh R., Nair S., Farr G., et al. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 97 (2002) 2670-2673
16. Okano N., Yamamoto K., Sakaguchi K., et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 25 (2003) 263-270
17. Misdraji J., Thiim M., and Graeme-Cook F.M. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 28 (2004) 471-478
18. Hofer H., Oesterreicher C., Wrba F., et al. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 59 (2006) 246-249
19. Miyake Y., Iwasaki Y., Terada R., et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res 37 (2007) 801-805
20. Zen Y., Notsumata K., Tanaka N., et al. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis?. Hum Pathol 38 (2007) 1669-1675
21. Ichai P., Duclos-Vallee J.C., Guettier C., et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 13 (2007) 996-1003
22. Viruet E.J., and Torres E.A. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J 17 (1998) 297-300
23. Czaja A.J., Rakela J., and Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 95 (1988) 448-453
24. Mistilis S.P., Skyring A.P., and Blackburn C.R. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality and survival. Australas Ann Med 17 (1968) 214-223
25. De Groote J., Fevery J., and Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 19 (1978) 510-513
26. Czaja A.J. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 29 (2009) 816-823
27. Gregorio G.V., Portmann B., Reid F., et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 25 (1997) 541-547
28. Czaja A.J., and Carpenter H.A. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 43 (2006) 532-538
29. Czaja A.J., Manns M.P., and Homburger H.A. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103 (1992) 1290-1295
30. Homberg J.C., Abuaf N., Bernard O., et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 7 (1987) 1333-1339
31. Czaja A.J., and Manns M.P. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol 90 (1995) 1206-1211
32. Czaja A.J., Carpenter H.A., Santrach P.J., et al. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 104 (1993) 1755-1761
33. Czaja A.J., Hay J.E., and Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc 65 (1990) 23-30
34. Heringlake S., Schutte A., Flemming P., et al. Presumed cryptogenic liver disease in Germany: High prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol 47 (2009) 417-423
35. Gassert D.J., Garcia H., Tanaka K., et al. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci 52 (2007) 2433-2437
36. Terjung B., Bogsch F., Klein R., et al. Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis. Eur J Med Res 9 (2004) 439-448
37. Baeres M., Herkel J., Czaja A.J., et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 51 (2002) 259-264
38. Ballot E., Homberg J.C., and Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 33 (2000) 208-215
39. Bridoux-Henno L., Maggiore G., Johanet C., et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2 (2004) 825-830
40. Czaja A.J., and Carpenter H.A. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 34 (2001) 659-665
41. Czaja A.J., Muratori P., Muratori L., et al. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 24 (2004) 322-329
42. Ludwig J., Czaja A.J., Dickson E.R., et al. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver 4 (1984) 105-116
43. Abdalian R., Dhar P., Jhaveri K., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 47 (2008) 949-957
44. Gregorio G.V., Portmann B., Karani J., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33 (2001) 544-553
45. Perdigoto R., Carpenter H.A., and Czaja A.J. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 14 (1992) 325-331
46. Czaja A.J. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 28 (1998) 360-365
47. Czaja A.J. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol 16 (2010) 934-947
48. Gohlke F., Lohse A.W., Dienes H.P., et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 24 (1996) 699-705
49. McNair A.N., Moloney M., Portmann B.C., et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 93 (1998) 777-784
50. Floreani A., Rizzotto E.R., Ferrara F., et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 100 (2005) 1516-1522
51. Chazouilleres O., Wendum D., Serfaty L., et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28 (1998) 296-301
52. Lohse A.W., zum Buschenfelde K.H., Franz B., et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 29 (1999) 1078-1084
53. Renou C., Bourliere M., Martini F., et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: complete biochemical and histological response to therapy with ursodesoxycholic acid. J Gastroenterol Hepatol 21 (2006) 781-782
54. Lim K.N., Casanova R.L., Boyer T.D., et al. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 96 (2001) 3390-3394
55. Nakamura K., Yoneda M., Yokohama S., et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 13 (1998) 490-495
56. Pando M., Larriba J., Fernandez G.C., et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 30 (1999) 1374-1380
57. Czaja A.J., Souto E.O., Bittencourt P.L., et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 37 (2002) 302-308
58. Hurlburt K.J., McMahon B.J., Deubner H., et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 97 (2002) 2402-2407
59. Scott J.D., and Garland N. Chronic liver disease in Aboriginal North Americans. World J Gastroenterol 14 (2008) 4607-4615
60. Minuk G.Y., Liu S., Kaita K., et al. Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can J Gastroenterol 22 (2008) 829-834
61. Zolfino T., Heneghan M.A., Norris S., et al. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 50 (2002) 713-717
62. D'Souza R., Sinnott P., Glynn M.J., et al. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 25 (2005) 325-330
63. Czaja A.J., and Donaldson P.T. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 174 (2000) 250-259
64. Donaldson P.T., and Czaja A.J. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 6 (2002) 707-725
65. Czaja A.J. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 6 (2008) 379-388
66. Verma S., Torbenson M., and Thuluvath P.J. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 46 (2007) 1828-1835
67. Flores Y.N., Yee Jr. H.F., Leng M., et al. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol 103 (2008) 2231-2238
68. Nguyen G.C., and Thuluvath P.J. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology 47 (2008) 1058-1066
69. Czaja A., and Carpenter H.A. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci 41 (1996) 305-314
70. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48 (2008) 169-176
71. Czaja A.J. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 48 (2008) 1540-1548
72. Yeoman A.D., Westbrook R.H., Al-Chalabi T., et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 50 (2009) 538-545
73. Neuhauser M., Bjornsson E., Treeprasertsuk S., et al. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 105 (2010) 345-353
74. Wiegard C., Schramm C., and Lohse A.W. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis 29 (2009) 254-261
75. Czaja A.J. Autoantibodies in autoimmune liver disease. Adv Clin Chem 40 (2005) 127-164
76. Bogdanos D.P., Mieli-Vergani G., and Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 29 (2009) 241-253
77. Czaja A.J. Autoantibodies as prognostic markers in autoimmune hepatitis. Dig Dis Sci (May 13, 2010) [Epub ahead of print]
78. Manns M., Gerken G., Kyriatsoulis A., et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1 (1987) 292-294
79. Stechemesser E., Klein R., and Berg P.A. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 18 (1993) 1-9
80. Costa M., Rodriguez-Sanchez J.L., Czaja A.J., et al. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol 121 (2000) 364-374
81. Gelpi C., Sontheimer E.J., and Rodriguez-Sanchez J.L. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A 89 (1992) 9739-9743
82. Wies I., Brunner S., Henninger J., et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355 (2000) 1510-1515
83. Volkmann M., Martin L., Baurle A., et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 33 (2001) 591-596
84. Czaja A.J., Donaldson P.T., and Lohse A.W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 97 (2002) 413-419
85. Ma Y., Okamoto M., Thomas M.G., et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 35 (2002) 658-664
86. Czaja A.J., Shums Z., and Norman G.L. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 35 (2002) 475-483
87. Seki T., Ota M., Furuta S., et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 103 (1992) 1041-1047
88. Yoshizawa K., Ota M., Katsuyama Y., et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol 42 (2005) 578-584
89. Miyakawa H., Kawashima Y., Kitazawa E., et al. Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun 21 (2003) 77-82
90. Toh B.H. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol 38 (1979) 621-628
91. Lidman K., Biberfeld G., Fagraeus A., et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 24 (1976) 266-272
92. Bottazzo G.F., Florin-Christensen A., Fairfax A., et al. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 29 (1976) 403-410
93. Fusconi M., Cassani F., Zauli D., et al. Anti-actin antibodies: a new test for an old problem. J Immunol Methods 130 (1990) 1-8
94. Czaja A.J., Cassani F., Cataleta M., et al. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 24 (1996) 1068-1073
95. Frenzel C., Herkel J., Luth S., et al. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol 101 (2006) 2731-2736
96. Chretien-Leprince P., Ballot E., Andre C., et al. Diagnostic value of anti-F-actin antibodies in a French multicenter study. Ann N Y Acad Sci 1050 (2005) 266-273
97. Granito A., Muratori L., Muratori P., et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 59 (2006) 280-284
98. Gueguen P., Dalekos G., Nousbaum J.B., et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 26 (2006) 495-505
99. Renaudineau Y., Dalekos G.N., Gueguen P., et al. Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol 34 (2008) 321-325
100. Martinez-Neira R., dos Remedios C.G., and Mackay I.R. An actin-myosin functional assay for analysis of smooth muscle (anti-microfilament) autoantibodies in human plasma. J Immunol Methods 338 (2008) 63-66
101. Lapierre P., Hajoui O., Homberg J.C., et al. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 116 (1999) 643-649
102. Muratori L., Sztul E., Muratori P., et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 34 (2001) 494-501
103. Renous R., Lapierre P., Djilali-Saiah I., et al. Characterization of the antigenicity of the formiminotransferase-cyclodeaminase in type 2 autoimmune hepatitis. Exp Cell Res 292 (2004) 332-341
104. Martini E., Abuaf N., Cavalli F., et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 8 (1988) 1662-1666
105. Abuaf N., Johanet C., Chretien P., et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 16 (1992) 892-898
106. Muratori L., Cataleta M., Muratori P., et al. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 42 (1998) 721-726
107. Muratori L., Cataleta M., Muratori P., et al. Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. J Immunol Methods 187 (1995) 259-264
108. Han S., Tredger M., Gregorio G.V., et al. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 21 (1995) 58-62
109. Lenzi M., Manotti P., Muratori L., et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 36 (1995) 749-754
110. Beland K., Lapierre P., Marceau G., et al. Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection. J Autoimmun 22 (2004) 159-166
111. Czaja A.J., Shums Z., and Norman G.L. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 37 (2004) 195-201
112. Philipp T., Durazzo M., Trautwein C., et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 344 (1994) 578-581
113. Durazzo M., Philipp T., Van Pelt F.N., et al. Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology 108 (1995) 455-462
114. Strassburg C.P., Obermayer-Straub P., Alex B., et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 111 (1996) 1576-1586
115. Crivelli O., Lavarini C., Chiaberge E., et al. Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin Exp Immunol 54 (1983) 232-238
116. Strassburg C.P., Kneip S., Topp J., et al. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275 (2000) 36164-36171
117. Obermayer-Straub P., and Manns M.P. Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Mol Biol Rep 23 (1996) 235-242
118. Manns M.P., and Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 26 (1997) 1054-1066
119. Donaldson P.T., Doherty D.G., Hayllar K.M., et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13 (1991) 701-706
120. Strettell M.D., Donaldson P.T., Thomson L.J., et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 112 (1997) 2028-2035
121. Doherty D.G., Donaldson P.T., Underhill J.A., et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 19 (1994) 609-615
122. Montano-Loza A.J., Carpenter H.A., and Czaja A.J. Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis. Liver Int 26 (2006) 1201-1208
123. Czaja A.J., Strettell M.D., Thomson L.J., et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 25 (1997) 317-323
124. Czaja A.J., Carpenter H.A., Santrach P.J., et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105 (1993) 1502-1507
125. Czaja A.J., Kruger M., Santrach P.J., et al. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 92 (1997) 2197-2200
126. Bittencourt P.L., Goldberg A.C., Cancado E.L., et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 94 (1999) 1906-1913
127. Fainboim L., Marcos Y., Pando M., et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol 41 (1994) 146-150
128. Goldberg A.C., Bittencourt P.L., Mougin B., et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol 62 (2001) 165-169
129. Jaeckel E. Animal models of autoimmune hepatitis. Semin Liver Dis 22 (2002) 325-338
130. Christen U., Holdener M., and Hintermann E. Animal models for autoimmune hepatitis. Autoimmun Rev 6 (2007) 306-311
131. Christen U., Hintermann E., and Jaeckel E. New animal models for autoimmune hepatitis. Semin Liver Dis 29 (2009) 262-272
132. Lapierre P., Djilali-Saiah I., Vitozzi S., et al. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 39 (2004) 1066-1074
133. Lapierre P., Beland K., Djilali-Saiah I., et al. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J Autoimmun 26 (2006) 82-89
134. Holdener M., Hintermann E., Bayer M., et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 205 (2008) 1409-1422
135. Manns M.P., Griffin K.J., Sullivan K.F., et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 88 (1991) 1370-1378
136. Kerkar N., Choudhuri K., Ma Y., et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 170 (2003) 1481-1489
137. Oldstone M.B. Molecular mimicry and immune-mediated diseases. FASEB J 12 (1998) 1255-1265
138. Bogdanos D.P., Choudhuri K., and Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 21 (2001) 225-232
139. Clemente M.G., Obermayer-Straub P., Meloni A., et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 82 (1997) 1353-1361
140. Clemente M.G., Meloni A., Obermayer-Straub P., et al. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 114 (1998) 324-328
141. Obermayer-Straub P., Perheentupa J., Braun S., et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology 121 (2001) 668-677
142. Bourdi M., Larrey D., Nataf J., et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest 85 (1990) 1967-1973
143. Manns M.P., Griffin K.J., Quattrochi L.C., et al. Identification of cytochrome P450IA2 as a human autoantigen. Arch Biochem Biophys 280 (1990) 229-232
144. Doherty D.G., Penzotti J.E., Koelle D.M., et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 161 (1998) 3527-3535
145. Gregorio G.V., Choudhuri K., Ma Y., et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 133 (2003) 404-413
146. Bogdanos D.P., Lenzi M., Okamoto M., et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 17 (2004) 83-92
147. Kammer A.R., van der Burg S.H., Grabscheid B., et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 190 (1999) 169-176
148. Albert L.J., and Inman R.D. Molecular mimicry and autoimmunity. N Engl J Med 341 (1999) 2068-2074
149. Vergani D., Choudhuri K., Bogdanos D.P., et al. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 6 (2002) 727-737
150. Djilali-Saiah I., Fakhfakh A., Louafi H., et al. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol 45 (2006) 844-850